Research funding
At the Division of Nuclear Medicine, a wide range of research projects are carried out (Study Center), partly on the division’s own initiative and partly in close cooperation with partners both within and outside the Medical University of Vienna.
Details can be found in the subcategories § 26 (ad personam projects funded by national and international research funding organizations) and § 27 (company-sponsored projects and contract research).
Project Title and Number: Inter-Organ Axen Bildgebung mittels PET, I 6174
PI: Univ. Prof. Dr. Marcus Hacker, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
Contact Person: Assoc. Prof. Priv.-Doz. DI Dr. Claudia Kuntner-Hannes
claudia.kuntner-hannes@meduniwien.ac.at, Tel.: +43 (0) 1 40160-64022
Duration: 01.01.2023 – 31.12.2026
Project Title and Number: Labeling – Evaluation – Model System, Project 5.2 – COMET K1 – microOne
PI: Univ. Prof. Dr. Marcus Hacker, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
Contact Person: Study Center, Division of Nuclear Medicine
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55360
Duration: 1.1.2023 – 30.6.2026
Project Title and Number: Das Hühnerei: ein Modell für die Blut-Hirn-Schranke, PAT8469124
PI: Mag. pharm. Dr. Theresa Balber
Contact Person: Mag. pharm. Dr. Theresa Balber
theresa.balber@meduniwien.ac.at, Tel.: +43 (0) 1 40160-78300
Duration: 01.05.2025 – 30.04.2028
Project Title and Number: EPILUCAFS, PIN 5320023
PI: Dr. rer. nat. MSc Chrysoula Vraka
Contact Person: Study Center, Division of Nuclear Medicine
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55315
Dr. rer. nat. MSc Chrysoula Vraka
chrysoula.vraka@meduniwien.ac.at
Tel.: +43 1 40400-58720 or -72350
Duration: 01.04.2025 – 31.03.2028
Project Title and Number: Metabolische Kontrolle von Altern und Krankheit – MetAGE
PI: Assoc. Prof. Priv.-Doz. Dr. Thomas Scherer, Department of Internal Medicine III, Division of Endocrinology and Metabolism
Contact Person: Assoc. Prof. Mag. Dr. Cecile Philippe, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
cecile.philippe@meduniwien.ac.at
Duration: 01.10.2024 – 30.09.2029
Project Title and Number: Comprehensive Strategies to Tackle Malignant Tumors: From Nanomedicine and Theranostics to Precision Medicine (EU-STRIKE – HORIZON 2021)
PI: Univ. Prof. Dr. Marcus Hacker, UKL für Radiologie und Nuklearmedizin, Klinische Abteilung für Nuklearmedizin
Contact Person: Ass.-Prof. Priv.-Doz. DI Dr. Claudia Kuntner-Hannes,
claudia.kuntner-hannes@meduniwien.ac.at, Tel.: +43 (0)1 40160-64022
Duration: 01.01.2023 – 31.12.2026
Project Title and Number: Minimally Invasive Therapy and Companion Diagnostics Using PET and Photodynamic Therapy (LightCure – HORIZON-2022)
PI: Dr. Oana Cristina Kulterer, UKL für Radiologie und Nuklearmedizin, Klinische Abteilung für Nuklearmedizin
oana.kulterer@meduniwien.ac.at
Contact Person: Studienzentrale der Klinischen Abteilung für Nuklearmedizin,
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55360
Duration: 01.01.2024 – 31.12.2029
Project Title and Number: Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics into the Brain (IM2PACT)
PI: Univ. Prof. Dr. Marcus Hacker, UKL für Radiologie und Nuklearmedizin, Klinische Abteilung für Nuklearmedizin
Contact Person: DI Thomas Wanek, UKL für Radiologie und Nuklearmedizin,
thomas.wanek@meduniwien.ac.at
Duration: 01.01.2023 – 31.12.2026
Project Title and Number: The PIAF Trial: Arterial 18F-FDG PET Imaging in Patients with a History of Myocardial Infarction and Elevated Inflammatory Status (PIAF)
PI: Univ. Prof. Dr. Marcus Hacker, UKL für Radiologie und Nuklearmedizin, Klinische Abteilung für Nuklearmedizin
Contact Person: Studienzentrale der Klinischen Abteilung für Nuklearmedizin,
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55360
Duration: 01.09.2021 – 09.05.2026
Project Title and Number: Combination Therapy in Combating Cholangiocarcinoma (COTHIC – LSC19-004)
PI: Univ. Prof. Dr. Marcus Hacker, UKL für Radiologie und Nuklearmedizin, Klinische Abteilung für Nuklearmedizin
Contact Person: Ass.-Prof. Priv.-Doz. DI Dr. techn. Claudia Kuntner-Hannes,
claudia.kuntner-hannes@meduniwien.ac.at, Tel.: +43 (0)1 40160-64022
Duration: 01.03.2021 – 01.09.2026
Project Title and Number: The PIAF Trial on Arterial 18FFDG PET Imaging Patients with History of Myocardial Infarction and Elevated Inflammatory Status. PIAF
PI: Univ. Prof. Dr. Marcus Hacker, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
Contact Person: Study Center, Division of Nuclear Medicine
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55360
Duration: 01.09.2021–09.05.2026
Funding Institution: International Atomic Energy Agency
Project Title and Number: An International Prospective Open-Label, Randomized Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care Versus Standard of Care Alone in Adult Male Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), PSMAddition
PI: Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 02.08.2021 – 31.12.2026
Funding Institution: Novartis
Project Title and Number: EPIK-B3: A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Assessing the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-Paclitaxel in Patients with Advanced Triple-Negative Breast Cancer with PIK3CA Mutation or PTEN Loss (CBYL719H12301)
PI: Univ. Prof. Dr. Christian Singer, Department of Obstetrics and Gynecology
Assoc.-Prof. PD Dr. Rupert Bartsch, Department of Internal Medicine I, Division of Oncology
Contact Person: Department of Obstetrics and Gynecology, Tel.: +43 (0)1 40400-28010
Department of Internal Medicine I, Division of Oncology, Tel.: +43 (0)1 40400-44260
Duration: 01.09.2020 – 30.06.2026
Funding Institution: Novartis
Project Title and Number: VIKTORIA-1: Phase III Open-Label Randomized Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant Versus Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor (CELC-G-301)
PI: Univ. Prof. Dr. Michael Seifert, Department of Obstetrics and Gynecology
Contact Person: Philipp Pappenscheller, Department of Obstetrics and Gynecology,
philipp.pappenscheller-hofboeck@meduniwien.ac.at
Duration: 01.05.2023 – 01.05.2026
Funding Institution: Celcuity Inc.
Project Title and Number: An International Prospective Open-Label Multicenter Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients with PSMA-Positive Oligometastatic Prostate Cancer (OMPC), CAAA617D12302
PI: Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Irena Gavranovic, Department of Urology,
irena.gavranovic@meduniwien.ac.at, Tel.: +43 (0)1 40400-60433
Duration: 01.07.2024 – 31.12.2029
Funding Institution: Novartis
Project Title and Number: ASCENT-07: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer
PI: Assoc.-Prof. PD Dr. Rupert Bartsch, Department of Internal Medicine I, Division of Oncology
Contact Person: Assoc.-Prof. PD Dr. Rupert Bartsch,
rupert.bartsch@meduniwien.ac.at, Tel.: +43 (0)1 40400-44260
Duration: 01.03.2024 – 28.02.2027
Funding Institution: Gilead Sciences
Project Title and Number: Neoadjuvant Lu-177 PSMA Radioligand Therapy for Patients with Oligometastatic Prostate Cancer Diagnosed Using Ga-68 PSMA-11 PET Imaging Followed by Radical Prostatectomy (PSMA-RLT in Oligometastatic PCa)
PI: Assoc.-Prof. Priv.-Doz. Dr. Sazan Rasul, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
Contact Person: Study Center, Division of Nuclear Medicine,
studienzentrale-nukmed@meduniwien.ac.at, Tel.: +43 (0)1 40400-55360
Duration: 01.06.2024 – 30.05.2027
Funding Institution: DSD Pharma
Project Title and Number: STELLAR: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
PI: Ao. Univ. Prof. Dr. Manuela Schmidinger, Department of Urology
Contact Person: Dr. Johannes Franke, Department of Urology,
johannes.franke@meduniwien.ac.at, Tel.: +43 (0)1 40400-60430
Duration: 01.12.2023 – 31.12.2028
Funding Institution: Exelixis
Project Title and Number: ARASTEP: A Randomized Double-Blind Placebo-Controlled Phase III Study of Darolutamide Plus Androgen Deprivation Therapy Compared with Placebo Plus ADT in Patients with High-Risk Biochemical Recurrence of Prostate Cancer
PI: Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.02.2024 – 31.12.2028
Funding Institution: Bayer
Project Title and Number: LUMEN-1: [177Lu]Lu-DOTATATE for Recurrent Meningioma – A Randomized Phase II Study
PI: Univ. Prof. Dr. Matthias Preusser, Department of Internal Medicine I, Division of Oncology
Contact Person: Calvin Abdelmalak, Department of Internal Medicine I, Division of Oncology,
calvin.abdelmalak@meduniwien.ac.at, Tel.: +43 (0)1 40400-44210
Duration: 01.07.2025 – 30.06.2028
Funding Institution: European Organisation for Research and Treatment of Cancer
Project Title and Number: EvoPAR-Prostate01: Randomized Double-Blind Placebo-Controlled Phase III Study of AZD5305 in Combination with Novel Hormonal Agents in Patients with Metastatic Castration-Sensitive Prostate Cancer
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.02.2025 – 29.02.2028
Funding Institution: AstraZeneca
Project Title and Number: EvoPAR-Breast01: A Randomized Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy in Patients with BRCA1, BRCA2 or PALB2 Mutated HR-Positive HER2-Negative Advanced Breast Cancer
PI: Priv.-Doz. Dr. Maximilian Marhold, Department of Internal Medicine I, Division of Oncology
Contact Person: Beate Rottenmanner, Department of Internal Medicine I, Division of Oncology,
beate.rottenmanner@meduniwien.ac.at, Tel.: +43 (0)1 40400-54590
Duration: 02.05.2025 – 30.04.2028
Funding Institution: AstraZeneca
Project Title and Number: ADELA Study: A Randomized Phase III Double-Blind Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients with ESR1-Mutated HR-Positive HER2-Negative Advanced Breast Cancer
PI: Assoc.-Prof. PD Dr. Rupert Bartsch, Department of Internal Medicine I, Division of Oncology
Contact Person: Assoc.-Prof. PD Dr. Rupert Bartsch,
rupert.bartsch@meduniwien.ac.at, Tel.: +43 (0)1 40400-44260
Duration: 01.09.2025 – 31.12.2028
Funding Institution: Medsir
Project Title and Number: Phase III Open-Label Multicenter Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (AMG20230239)
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.11.2025 – 31.12.2028
Funding Institution: Amgen
Project Title and Number: Phase III Open-Label Multicenter Randomized Study of Xaluritamig Versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Chemotherapy (AMG20230005)
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.07.2025 – 31.12.2029
Funding Institution: Amgen
Project Title and Number: rechARge: A Phase III Two-Part Randomized Open-Label Adaptive Study Comparing BMS-986365 Versus Investigator’s Choice Therapy in Metastatic Castration-Resistant Prostate Cancer (CA071-1000)
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.06.2025 – 31.12.2029
Funding Institution: Bristol Myers Squibb
Project Title and Number: FMGX-CS-302: An Interventional Phase III Open-Label Study Investigating the Efficacy and Safety of Fosmanogepix in Adult Patients with Invasive Mold Infections
PI: Priv.-Doz. Dr. PhD Matthias Vossen, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine
Contact Person: Priv.-Doz. Dr. PhD Matthias Vossen,
Tel.: +43 (0)1 40400-44400
Duration: 01.10.2025 – 31.12.2028
Funding Institution: Basilea Pharmaceutica
Project Title and Number: Phase Ib/II Dose-Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer in Combination with Carboplatin, Etoposide and Atezolizumab (CAAA601A42101)
PI: Ao. Univ. Prof. Dr. Markus Raderer, Department of Internal Medicine I, Division of Oncology
Contact Person: Amirhossein Sadeghi, Department of Internal Medicine I, Division of Oncology,
amirhossein.sadeghi@meduniwien.ac.at
Duration: 02.05.2025 – 31.12.2028
Funding Institution: Novartis
Project Title and Number: Phase II Randomized Open-Label Multi-Center Study of JSB462 (Luxdegalutamide) in Combination with Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (CJSB462B12201)
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Dr. Aravind Sajeev, Department of Urology,
aravind.sajeev@meduniwien.ac.at
Duration: 01.10.2025 – 31.12.2028
Funding Institution: Novartis
Project Title and Number: AcTFirst: A Phase III Open-Label Multi-Center Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer CAAA817B12301
PI: Ao. Univ. Prof. Dr. Gero Kramer, Department of Urology
Contact Person: Nadine Rainer, Department of Urology,
nadine.rainer@meduniwien.ac.at, Tel.: +43 (0)1 40400-60432
Duration: 01.06.2026 – 31.12.2029
Funding Institution: Novartis
Project Title and Number: PL2 – Intra- and Inter-Cellular Architecture in Health and Disease (Adjunct PI)
PI: Dr. Barbara Katharina Geist, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, barbara.geist@meduniwien.ac.at
Contact Person: Dr. Barbara Katharina Geist, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, barbara.geist@meduniwien.ac.at
Duration: 01.09.2025 – 31.12.2027
Funding Institution: Ludwig Boltzmann Gesellschaft